A functional comparison of two transplantable syngeneic mouse models of melanoma: B16F0 and YUMM1.7

David J. Klinke II[1] ✉*, Alanna Gould[2], Anika Pirkey[1], Atefeh Razazan[3], and Wentao Deng[4]

[1]Department of Chemical and Biomedical Engineering, West Virginia University, Morgantown, WV
[2]Department of Biochemistry, The Medical College of Wisconsin
[3]Department of Physiology, Pharmacology and Toxicology, West Virginia University, Morgantown, WV
[4]The MD Anderson Cancer Center at University of Texas
*Lead Contact

The B16 murine melanoma cell lines are considered the gold standard for testing melanoma immunotherapies due to low treatment success rates. However, the clinical relevance of these models has been questioned due to a mutational landscape void of driver mutations typically seen in human melanomas and a tendency to form necrotic cores at high tumor volumes. Creating the YUMM1.7 line addressed these limitations by providing an additional contextually consistent model with a more clinically relevant genetic background. The combined use of both models can generate stronger studies in melanoma immunology and immunotherapy. However, to date, there have been no direct functional comparisons of the characteristics of these two models to inform the design of such studies. To address this, we conducted a series of functional experiments to characterize the kinetics of tumor growth, chemotherapeutic sensitivity, and immunogenicity of these models. We found that the B16F0 model had faster intrinsic tumor growth rates, was more susceptible to lysis by tumor-specific CD8+ T cells, and secreted higher levels of the angiogenic factors VEGF and Ang2. Meanwhile, the YUMM1.7 model was more sensitive to chemotherapeutic treatment, secreted higher levels of chemokines CCL2, CXCL1, and CX3CL1, and showed higher infiltration of lymphocyte and myeloid subsets relative to tumor size. Overall, these results suggest that the YUMM1.7 model may be better suited for *in vivo* studies of mechanisms that require a wide window of opportunity for observation and intervention, such as immune response. However, angiogenesis and immunotherapy studies may benefit from a more in-depth comparative analyses of both models.

In vivo mouse tumor models | cancer immunology | Markov Chain Monte Carlo

Correspondence: ***david.klinke@mail.wvu.edu***

Introduction

Murine cancer cell lines are widely used to study the interaction between malignant cells and host immunity *in vivo* (1) with the B16 cell lines being some of the most frequently used. These clonal cell lines were isolated by Dr. Isaiah J. Fidler in the mid-1970s and are derived from a spontaneously arising melanoma in an aged male C57BL/6 mouse (2). Different subclones were derived based on their relative propensity to metastasize, with B16F0 having the least potential and B16F10 having the most potential to metastasize. These B16 variant cell lines are used to study biology intrinsic to melanoma cells and extrinsic pathways associated with melanoma metastasis and evasion of host anti-tumor immunity. Although B16 cell lines have long been thought of as the gold standard of immunocompetent murine melanoma models, as they provide a tough test of immunotherapy (3, 4), the mutational landscape of the B16 line is unlike that seen in human melanoma (5) particularly in the context of common driver mutations.

To address this limitation, the Yale University Mouse Melanoma (YUMM) cell lines were developed as immunocompetent cell lines with defined genetic alterations. In particular, the YUMM1.7 cell line is derived from a 4-hydroxytamoxifen-induced melanoma tumor in a male C57BL/6 mouse (6). This cell line is homozygous negative for wild-type PTEN and CDKN2 and harbors the BRAF V600E mutation. YUMM1.7 cells can be efficiently used for basic science studies of melanoma biology and immunology and to identify and evaluate new immunotherapies. Introducing the YUMM1.7 model provides the research community with additional diversity that can be integrated into their work and presents a more human-relevant genetic background to study cancer immunology while remaining contextually consistent. In this work, we will characterize the tumor progression, chemotherapeutic sensitivity, and immune response of these two cell lines to provide context for how future works can best leverage their similarities and differences to generate robust results in pre-clinical immunology and immunotherapy studies.

Results and Discussion

***In vivo* tumor growth kinetics in C57BL/6 and NSG mice.** Immunocompetent C57BL/6 mice and severely immunocompromised NSG mice were subcutaneously (s.c.) injected with wild-type B16F0 or YUMM1.7 tumor cells. B16F0 tumors grew rapidly, reaching 1000 mm^3 in diameter within two weeks in C57BL/6 and three weeks in NSG. (Fig. 1A). In contrast, YUMM1.7 treated animals succumbed to a large progressive tumor in just over four weeks (Fig. 1B). Because the tumor growth of both cell lines consistently follows a log-linear growth trajectory in both C57BL/6 and NSG mice, the tumor size at any point in time can be described as a function of the initial bolus size of tumor-initiating cells (C_{T0}) and the net growth rate ($k = k_P$-k_D) (Fig. 1C). Tu-

mor growth in severely immunocompromised NSG mice was used to estimate intrinsic proliferation rate constants (k_P) of both cell lines (Fig. 1D). We noted that the k_P of the B16F0 line was significantly higher than the YUMM1.7 line (median k_P YUMM1.7 = 0.44 day^{-1} vs B16F0 = 0.65 day^{-1}). In the immunocompetent C57BL/6 model, we assumed that the net proliferation rate was a result of both the intrinsic proliferation rate and the loss of tumor size due to immune-related cell death (k_D). This assumption allows one parameter to be used to represent all anti-tumor immunity mechanisms present in the C57BL/6 model and absent in the NSG model. The difference in immune-related cell death can then be inferred by comparing the net growth rate of either cell line in NSG versus C57BL/6, which is expressed as a log-ratio (Fig. 1E). The YUMM1.7 cell line exhibited lower log-ratios than the B16F0 cell line (median log-ratio B16F0 = 0.195 vs median log-ratio YUMM1.7 = -0.009). In addition, net tumor growth rates of the YUMM1.7 cell line in C57BL/6 and NSG mice were not statistically different, as evident by the posterior distribution of the log ratio being centered around 0, while the growth rate of the B16F0 model was significantly higher in NSG mice. Both of these findings are consistent with literature citing that genetically engineered models are typically less immunogenic than spontaneous tumor models induced by carcinogens (1, 7–9). This reduced immunogenicity of the YUMM1.7 cell line motivated exposure to UV radiation to create the YUMMER1.7 derivative (10).

The faster intrinsic growth rate of the B16F0 tumors *in vivo* has potential implications in experimental design. When measuring changes in tumor size as an indicator of a productive anti-tumor response to a therapy, it takes time for the biological mechanisms elicited by the therapy within the system to mount a sufficient response. For instance, when a therapy is designed to elicit a new adaptive anti-tumor immune response, it takes up to 14 days to fully activate the adaptive immune system (11). By this time, B16F0 tumors are often large (> 1000 mm^3) and begin developing ulcers and a necrotic core (4). These issues persist despite our use of female C57BL/6 mice, which has been shown to decrease B16F0 tumor volume and increase immune cell infiltration in comparison to male mice (12), and this combination of symptoms significantly shortens the window of opportunity for observation. On average, B16F0 and YUMM1.7 tumor volumes in C57BL/6 mice reached approximately 1000 mm^3 by days 18 and 28, respectively, with all mice in the B16F0 cohorts typically requiring humane euthanasia by 21 days.

In addition to this short window of opportunity for mechanistic study, most experimental immunotherapies published are only able to show successful slowing or delaying of tumor growth in B16F0 tumors when treatment is administered prior to day 5 post-inoculation, which is typically before palpable tumors present (13). With these problems in mind, use of the YUMM1.7 model, although slower to establish measurable tumors, allows for a significantly improved experimental timeline to measure changes in mechanisms with slower response times and inherent system dynamics.

Impact of chemotherapeutic drugs on cell viability. Given that chemotherapy drugs have been used as a first-line treatment for melanoma, we first tested the impact of three chemotherapy drugs on the viability of B16F0 and YUMM1.7 cell lines. The three drug panel included PLX-4720, an inhibitor of BRAFV600E; mitoxantrone, a chemotherapy drug that causes DNA damage, apoptosis, and immunologic cell death (14, 15); and iCRT14, a Wnt pathway inhibitor. B16F0 and YUMM1.7 cells were exposed to PLX-4720 at concentrations ranging from 0-12 μM/ml, mitoxantrone from 0-200 nM/ml, or iCRT14 from 0-25 μM/ml for 24 h. Our results showed that there was a prominent dose-dependent decrease in cell viability in both treated cell lines after 24 h. Among the three small molecule drugs, PLX-4720 and mitoxantrone had a differential effect between the two cell lines. The IC50's for PLX-4720 were almost a factor of 100 different, with 138.6 μM for B16F0 and 1.734 μM for YUMM1.7. This was expected, as the YUMM1.7 cell line was derived from mice harboring the activating BRAFV600E mutation while the B16F0 line retains wild-type BRAF. Mitoxantrone had a slightly less differential effect than PLX-4720, with observed IC50s of 68.07 nM for B16F0 and 9.528 nM for YUMM1.7 cells. While iCRT14 also had a significant dose-dependent effect on viability, the IC50s were similar with values of 3.43 μM for B16F0 and 3.37 μM for YUMM1.7 cell lines (Fig. 2). In terms of relative toxicity, mitoxantrone was the most toxic with IC50's in the nanomolar range compared to the micromolar range for iCRT14 and PLX-4720.

Sensitivity to antigen-specific CD8+ T cell responses. CD8+ T lymphocytes were isolated and purified from PMEL1 C57BL/6 mice and pre-activated with PMEL1 CD8+ T cell specific peptide (hgp100$_{25-33}$) for two days. These pre-activated PMEL1 CD8+ T cells were then co-cultured with target cells at the indicated effector to target ratio for 4 hours. Using a cytotoxicity assay, both targeted cell lines exhibited an increase in cytotoxicity with increasing effector to target ratio. Lysis of B16F0 cells by hgp100$_{25-33}$-activated T lymphocytes was significantly higher than that of YUMM1.7 cells across all effector to target ratios (Fig. 3., p-value ≤ 0.01). Next, we explored possible reasons for this difference.

The pro-inflammatory cytokine IFN-γ plays an important role in regulating immune responses within the tumor microenvironment (TME). IFN-γ directly acts on tumor cells to induce MHC class I expression. Studies show that exposure to rmIFN-γ *in vitro* increases surface expression of MHC class I on tumor cells, thus potentially increasing their recognition by cytotoxic CD8+ T lymphocytes. To compare the extent of this effect in the two cell lines, wild-type B16F0 and YUMM1.7 cell lines were incubated with or without 250 U/mL of rmIFN-γ. Under normal culture conditions, unstimulated B16F0 and YUMM1.7 cells expressed statistically similar low levels of H2K^b and H2D^b (Fig. 4 left column, rows B and C). The B16F0 cell line expressed significantly higher levels of PD-L1 at baseline than the YUMM1.7 line, but levels were still relatively low (Fig. 4 left column, row

A). Both cell lines upregulated PD-L1, H2K^b and H2D^b after IFN-γ stimulation, though the difference in expression levels was greater in B16F0 than in YUMM1.7 (Fig. 4 middle column).

Relative abundance of tumor-infiltrating immune subsets and tumor-secreted factors. To characterize the differences in immune cell infiltration to the different cell lines, single cell suspensions from tumors generated by inoculating C57BL/6 mice with wild-type B16F0 or YUMM1.7 cells were aliquoted among three antibody panels and characterized via flow cytometry as described previously (16). Among tumors of similar sizes, B16F0 tumors showed significantly lower CD45+ cell infiltration compared to YUMM1.7 tumors (Fig. 5A, p-value ≤ 0.01). The relative prevalence of NK cells, CD8+ T-cells, and CD4+ T-cells was higher in the YUMM1.7 cell line than the B16F0 line (p-value for NK cells ≤ 0.01, CD8+ T-cells ≤ 0.05, CD4+ T-cells ≤ 0.01). In contrast, B-cells were significantly more prevalent in the B16F0 tumors compared to the YUMM1.7 tumors (Fig. 5B, p-value ≤ 0.001). In addition to assaying changes in T, B, and NK cells, we also reviewed changes in the myeloid compartment, focusing on CD11c+ and CD11c- macrophages and three different myeloid derived suppressor cell (MDSC) populations: CD11c+ monocytic (CD11c+ Mo-MDSC), CD11c- monocytic (Mo-MDSC), and polymorphonuclear (PMN-MDSC) (Fig. 5C). Mo-MDSCs and CD11c- macrophages were significantly less prevalent in YUMM1.7 tumors compared to B16F0 tumors (p-values ≤ 0.01) while CD11c+ macrophages, CD11c+ Mo-MDSC, and PMN-MDSCs were significantly more prevalent in the YUMM1.7 tumors (p-values CD11+ macs and CD11C+ Mo-MDSCs ≤ 0.01, PMN-MDSCs ≤ 0.05).

To identify potential secreted factors that underpin the observed differences in immune cell infiltration between these two tumor models, we measured cytokine, chemokine, and growth factor production by wild-type YUMM1.7 and B16F0 cells *in vitro* using the R&D Systems Mouse XL Cytokine Array (Fig. 6). As differences in angiogenesis between B16F0 and YUMM1.7 tumors may underpin differences in total CD45+ cell infiltration, we found that conditioned media from B16F0 cells contained higher levels of the angiogenic factors Vascular Endothelial Growth Factor (VEGF) and Angiopoietin-2 (Ang2) compared to that from YUMM1.7 cells. VEGF and Ang2 are known to promote the growth of new, immature blood vessels, and Ang2 has been shown to inhibit blood vessel maturation and normalization by inhibiting Ang1 signaling via Tie2 in vascular endothelial cells (17, 18).

In addition, the angiogenic response to VEGF exhibits a biphasic response where angiogenesis increases with VEGF at low expression levels while high VEGF expression has an inhibitory effect (19). It is known that tumors formed by subcutaneous injection of B16 cells become necrotic when allowed to grow larger than 1000 mm^3, which occurs within 14-21 days (4). Indeed, in our hands, YUMM models tend to produce solid tumors with more developed blood vessels, while tumors derived from B16 models tend to be more avascular and necrotic. Taken together, the two models may provide an interesting context to explore how modulating these different angiogenic factors, VEGF and Ang2, influence immune cell infiltration within tumors, a first step in engaging an anti-tumor immune response.

Within the CD45+ compartment, observed differences among immune cell composition may be explained by chemokine and cytokine expression differences. Notably, the chemokines CCL2, CXCL1, and CX3CL1 were upregulated in the conditioned media from YUMM1.7 cells compared to that from B16F0 cells. CCL2 and CXCL1 have previously been associated with MDSC infiltration into tumors via their respective receptors, CCR2 and CXCR2 (20, 21). CX3CL1 has been associated with the accumulation of tumor-associated macrophages (TAMs) and their polarization toward a protumor M2-like phenotype (22, 23). Meanwhile, conditioned media from B16F0 cells contained higher levels of CCL5, which has been associated with the recruitment and activation of TAMs, MDSCs and T regulatory cells (T-regs) (24–28). While these immune cell subsets don't all map onto the cell subsets profiled by our flow cytometry panel (Fig. 5), we noted that the only myeloid subsets that showed significantly higher infiltration in B16F0 tumors than YUMM1.7 tumors were CD11c- Macrophages and Mo-MDSCs, while YUMM1.7 tumors contained more CD11c+ Macrophages and MDSCs. This may be explained by the increased abundance of CCL2 in YUMM1.7 tumors. CCL2 has been shown to promote adhesion of monocytes to vascular endothelial cells by increasing surface expression of CD11b and CD11c on monocytes. It has also been shown to promote the differentiation of monocytes into MDSCs (29). Additionally, Macrophage Colony Stimulating Factor (M-CSF/CSF-1), which is also slightly upregulated in YUMM1.7 cells, has been shown to bind the CSF-1 receptor expressed by CD11c+ macrophages and, in combination with CCL2, promote their polarization toward an immunosuppressive M2-like phenotype (30).

Conclusions

The B16F0 cell line has long been thought of as the gold standard for pre-clinical testing of melanoma immunotherapies due to the difficult bar it sets for success (3, 4). However, the YUMM cell lines developed at Yale University offer an additional possibility that addresses the lack of similarity in the mutational landscape between human and murine melanoma while holding some benefits over the B16F0 line in certain contexts (5, 6). The B16F0 cell line has a significantly faster intrinsic growth rate than the YUMM1.7 line. When combined with its tendency to form a necrotic core and ulcerate at high tumor volumes (4), this fast growth rate can lead to difficulty in studying mechanisms that require longer response times, such as eliciting a primary adaptive immune response. In contrast, the YUMM1.7 model takes significantly longer to form palpable tumors, but offers a wide window of opportunity to study these slower mechanisms because the mouse model's health is not jeopardized by necrosis or ulcerations that lead to early sacrifice.

The lack of necrotic core in the YUMM1.7 model may be due to changes in the secreted factors present between the two models. The B16F0 model shows higher levels of VEGF and Ang2 in conditioned media, potentially leading to the formation of immature blood vessels or the inhibition of vessel formation (17–19). Studies of angiogenesis in melanoma tumors may benefit from a comparative analysis of these two cell lines, as modulation of secreted factors to improve angiogenesis may provide an additional pathway to improving the efficacy of cancer immunotherapies by increasing CD45+ immune infiltration, which was significantly lower in the B16F0 tumors compared with YUMM1.7 tumors. While additional work may be required to further parse these complicated profiles of secreted proteins, these results highlight a more complicated and nuanced biology associated with two seemingly similar pre-clinical mouse models for melanoma.

Materials and Methods

Mice. 6- to 8-week-old female C57BL/6 and NSG mice were purchased from Charles River Laboratories and The Jackson Laboratory, respectively, and randomly assigned to treatment groups for tumor growth assays. 8- to 12-week-old female transgenic B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J (PMEL1) mice were purchased from The Jackson Laboratory and used as a source of transgenic CD8+ T cells. All animal experiments were approved by the West Virginia University (WVU) Institutional Animal Care and Use Committee and performed on-site (IACUC Protocol #1604002138). Mice were co-housed in sterilized micro-isolator cages and facility sentinel animals were regularly screened for specific pathogenic agents.

Reagents and Cell culture. The mouse melanoma line B16F0 (purchased in 2008, RRID: CVCL_0604) was obtained from American Tissue Culture Collection (ATCC, Manassas, VA). The mouse melanoma line YUMM1.7 (received in September 2017, RRID: CVCL_JK16) was a gift from Drs. William E. Damsky and Marcus W. Bosenberg (Yale University) (6). The cells were cultured at 37°C in 5% CO_2 in high-glucose DMEM (Cellgro/Corning, NY) supplemented with L-glutamine (Lonza, NJ), 1% penicillin-streptomycin (Gibco, ThermoFisher Scientific, MA), and 10% heat-inactivated fetal bovine serum (Hyclone). All cell lines were revived from frozen stock, used within 10-15 passages that did not exceed a period of 6 months, and routinely tested for mycoplasma contamination by PCR. Mitoxantrone hydrochloride, PLX-4720 and iCRT14 were purchased from Selleckchem, Cayman Chemical Co, and Sigma-Aldrich, respectively. The peptide hgp100$_{25-33}$ (KVPRNQDWL) was purchased from GenScript. Recombinant mouse IL-2 was purchased from eBioscience (ThermoFisher Scientific, MA). Recombinant mouse IFN-γ, PE-conjugated anti-mouse CD274 (PD-L1), PerCP/Cy5.5-conjugated anti-mouse H-2Db, and APC-conjugated anti-mouse H-2Kb were purchased from BioLegend (San Diego, CA).

***In vivo* tumor growth.** For tumor challenge, mice were implanted subcutaneously on the right flank with 3x10^5 B16F0 or 5x10^5 YUMM1.7 cells in PBS. Tumor growth was monitored every two days by measuring two perpendicular diameters of the tumor using calipers. The tumor volume was calculated according to the formulation (π/6 x length x width^2). For ethical considerations, mice were sacrificed when tumor burden was significant enough to affect daily life (difficulty moving, weight loss, inability to feed or gain access to water, etc).

Flow cytometry. Four B16F0 and three YUMM1.7 tumors were surgically removed from C57BL/6 mice after euthanasia once tumors reached between 1000 and 1500 mm^3. Single-cell suspensions were obtained by enzymatically digesting the excised tumors using the Tumor Dissociation Kit and gentleMACS C system (Miltenyi Biotec, Auburn, CA). In addition to following the manufacturer's instructions, the gentleMACS program 37C_m_TDK_2 was used for YUMM1.7 tumors and 37C_m_TDK_1 was used for B16F0 tumors. Following red blood cell lysis, the remaining single-cell suspensions were washed and stained with Live/Dead Fixable Pacific Blue Dead Cell Stain Kit (ThermoFisher) and blocked with Mouse BD Fc Block (BD Biosciences). Cell surfaces were then stained with one of three antibody mixes that focused on T cells (CD45, CD3, CD4, CD8, and PD1), NK and B cells (CD45, CD3, B220, NK11, DX5, and PD1), and myeloid cells (CD45, CD11b, CD11c, Gr-1, F4/80, and MHCII) and quantified by flow cytometry, as described previously (16).

***In vitro* studies.** For cell viability assays, B16F0 and YUMM1.7 were treated with Mitoxantrone, iCRT14, and PLX-4720 at the indicated concentrations for 24 hours, 37°C and in 5% CO2. The cells were harvested and seeded in 96-well black plates with 5000 cells per well. Cell viability was determined using the ATPlite Luminesence ATP Detection Assay System (Perklin Elmer, USA) according to the manufacturer's instructions.

To assay antigen-specific cytotoxicity, splenocytes from PMEL1 mice were pre-activated *in vitro* for two days with 1 μM of the PMEL1 CD8+ T cell specific peptide (hgp100$_{25-33}$ (KVPRNQDWL)) in the presence of 100 U/mL of rmIL-2. On days two and four the cells were washed and re-cultured with fresh media containing 100 U/mL of rmIL-2. Pre-activated PMEL1 CD8+ T cells were co-cultured for 4 hours with target cells, at the indicated effector to target ratios, to assess cytotoxicity that was quantified using a CyQUANT LDH Cytotoxicity assay (Invitrogen).

To assay PD-L1 and MHC class I expression, wild-type B16F0 and YUMM1.7 cell lines were stimulated directly *in vitro* in the presence and absence of rmIFNγ (250 U/ml) for 24 hours. Cells were washed twice with 200 μL fluorescence-activated cell sorting (FACS) wash buffer, pelleted by centrifugation at 2000 RPM for 5 minutes and resuspended in 200 μL of FACS wash buffer before monoclonal antibody staining. Cells were stained in the dark at 4°C for 30 minutes

by using a cocktail of fluorochrome-conjugated anti-mouse antibodies for PD-L1/PE, H-2K^b/APC and H-2D^b/PerCP-Cy5.5. Stained cells were washed in flow wash buffer and fixed in 1% paraformaldehyde for 1 hour at 4°C. The events were acquired using a BD LSR Fortessa (BD Biosciences) flow cytometry with FACSDiva software. Data were analyzed with FCS Express 6.0 (DeNovo Software, CA) and R.

To collect tumor-conditioned media (TCM), wild-type B16F0 and YUMM1.7 cells were grown in complete DMEM until 80% confluency, washed with PBS (Cellgro/Corning, NY) and incubated for 48 h in FBS-free DMEM. TCM were then centrifuged at 3,000 g and 4°C for 15 min, and the supernatant collected and filtered. Cytokines, chemokines, and growth factors in TCM were detected with the Proteome Profiler Mouse XL Cytokine Array (R&D Systems, MN), following the manufacturer's instructions.

Statistical analysis. Cytotoxicity assay and cell viability data were analyzed by a two-tailed, unpaired Student's t-test. A p-value of less than 0.05 was considered statistically significant. Tumor growth data were analyzed by estimating the growth rate of the tumors using a log-linear tumor growth model and a Markov Chain Monte Carlo approach to generate the posterior distribution in the rate parameters, as described in (31).

ACKNOWLEDGEMENTS

This work was supported by the National Science Foundation (DJK) and National Cancer Institute (NCI 1R01CA193473 to DJK). Any opinion, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation or National Cancer Institute. The authors would like to thank Audry Fernandez for her assistance in conducting this study.

AUTHOR CONTRIBUTIONS

These contributions follow the International Committee of Medical Journal Editors guidelines: http://www.icmje.org/recommendations/. Conceptualization: DJK; Study Design: DJK; Data Acquisition: DJK, WD, AF, AR; Data Analysis: DJK, AP; Data Interpretation: DJK, AP, AG; Funding acquisition: DJK; Methodology: DJK; Project administration: DJK; Software: DJK; Supervision: DJK; Writing - original draft: DJK, WD, AF, AR, AP, AG; Writing - review & editing: DJK, AP, AG.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Bibliography

1. K. A. Connolly, B. Fitzgerald, M. Damo, and N. S Joshi. Novel mouse models for cancer immunology. *Annu. Rev. Cancer Biol.*, 6(1):269–291, Apr 2022.
2. I. J. Fidler. Biological behavior of malignant melanoma cells correlated to their survival in vivo. *Cancer Res*, 35(1):218–224, Jan 1975.
3. W. W. Overwijk and N. P. Restifo. B16 as a mouse model for human melanoma. *Curr Protoc Immunol*, Chapter 20:Unit 20.1, May 2001.
4. Z. Ya, Y. Hailemichael, W. Overwijk, and N. P. Restifo. Mouse model for pre-clinical study of human cancer immunotherapy. *Curr Protoc Immunol*, 108:1–20, Feb 2015.
5. W. Zhong, J. S. Myers, F. Wang, K. Wang, J. Lucas, E. Rosfjord, J. Lucas, A. T. Hooper, S. Yang, L. A. Lemon, M. Guffroy, C. May, J. R. Bienkowska, and P. A. Rejto. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. *BMC Genomics*, 21(1):2, Jan 2020.
6. K. Meeth, J. X. Wang, G. Micevic, W. Damsky, and M. W. Bosenberg. The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. *Pigment Cell Melanoma Res*, 29(5):590–597, Sep 2016.
7. M. DuPage and T. Jacks. Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. *Curr Opin Immunol*, 25(2):192–199, Apr 2013.
8. J. W. Lee, C. A. Komar, F. Bengsch, K. Graham, and G. L. Beatty. Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery. *Curr Protoc Pharmacol*, 73:1–14, Jun 2016.
9. D. G. McFadden, K. Politi, A. Bhutkar, F. K. Chen, X. Song, M. Pirun, P. M. Santiago, C. Kim-Kiselak, J. T. Platt, E. Lee, E. Hodges, A. P. Rosebrock, R. T. Bronson, N. D. Socci, G. J. Hannon, T. Jacks, and H. Varmus. Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. *Proc Natl Acad Sci U S A*, 113(42):E6409–E6417, Oct 2016.
10. J. Wang, C. J. Perry, K. Meeth, D. Thakral, W. Damsky, G. Micevic, S. Kaech, K. Blenman, and M. Bosenberg. UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model. *Pigment Cell Melanoma Res*, 30(4):428–435, Jul 2017.
11. H. Miao, J. A Hollenbaugh, M. S Zand, J. Holden-Wiltse, T. R Mosmann, A. S Perelson, H. Wu, and D. J Topham. Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza a virus. *Journal of virology*, 84:6687–98, 7 2010. ISSN 1098-5514. doi: 10.1128/JVI.00266-10.
12. P. P Dakup, K. I Porter, A. A Little, H. Zhang, and S. Gaddameedhi. Sex differences in the association between tumor growth and t cell response in a melanoma mouse model. *Cancer immunology, immunotherapy : CII*, 69:2157–2162, 10 2020. ISSN 1432-0851. doi: 10.1007/s00262-020-02643-3.
13. F. T Wen, R. A Thisted, D. A Rowley, and H. Schreiber. A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. *Oncoimmunology*, 1:172–178, 3 2012. ISSN 2162-4011. doi: 10.4161/onci.1.2.18311.
14. S. Fujimoto and M. Ogawa. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. *Cancer Chemother Pharmacol*, 8(2):157–162, 1982.
15. A. Q. Sukkurwala, S. Adjemian, L. Senovilla, M. Michaud, S. Spaggiari, E. Vacchelli, E. E. Baracco, L. Galluzzi, L. Zitvogel, O. Kepp, and G. Kroemer. Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. *Oncoimmunology*, 3:e28473, 2014.
16. A. Fernandez, W. Deng, S. L. McLaughlin, A. C. Pirkey, S. L. Rellick, A. Razazan, and D. J. Klinke. Cell Communication Network factor 4 promotes tumor-induced immunosuppression in melanoma. *EMBO Rep*, 23(4):e54127, Apr 2022.
17. H. Tao Yuan, E. V. Khankin, S. A. Karumanchi, and S. M. Parikh. Angiopoietin 2 is a partial agonist/antagonist of tie2 signaling in the endothelium. *Molecular and Cellular Biology*, 29: 2011–2022, 4 2009. ISSN 1098-5549. doi: 10.1128/MCB.01472-08.
18. P. Saharinen, L. Eklund, K. Pulkki, P. Bono, and K. Alitalo. Vegf and angiopoietin signaling in tumor angiogenesis and metastasis. *Trends in Molecular Medicine*, 17:347–362, 7 2011. ISSN 14714914. doi: 10.1016/j.molmed.2011.01.015.
19. G. Carpentier, S. Berndt, S. Ferratge, W. Rasband, M. Cuendet, G. Uzan, and P. Albanese. Angiogenesis analyzer for imagej — a comparative morphometric analysis of "endothelial tube formation assay" and "fibrin bead assay". *Scientific Reports*, 10:11568, 7 2020. ISSN 2045-2322. doi: 10.1038/s41598-020-67289-8.
20. B. Huang, Z. Lei, J. Zhao, W. Gong, J. Liu, Z. Chen, Y. Liu, D. Li, Y. Yuan, G.-M. Zhang, and Z.-H. Feng. Ccl2/ccr2 pathway mediates recruitment of myeloid suppressor cells to cancers. *Cancer Letters*, 252:86–92, 7 2007. ISSN 03043835. doi: 10.1016/j.canlet.2006.12.012.
21. M. Taki, K. Abiko, T. Baba, J. Hamanishi, K. Yamaguchi, R. Murakami, K. Yamanoi, N. Horikawa, Y. Hosoe, E. Nakamura, A. Sugiyama, M. Mandai, I. Konishi, and N. Matsumura. Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via cxcr2 ligand upregulation. *Nature Communications*, 9:1685, 4 2018. ISSN 2041-1723. doi: 10.1038/s41467-018-03966-7.
22. Y. Ishida, Y. Kuninaka, Y. Yamamoto, M. Nosaka, A. Kimura, F. Furukawa, N. Mukaida, and T. Kondo. Pivotal involvement of the cx3cl1-cx3cr1 axis for the recruitment of m2 tumor-associated macrophages in skin carcinogenesis. *Journal of Investigative Dermatology*, 140: 1951–1961.e6, 10 2020. ISSN 0022-202X. doi: 10.1016/j.jid.2020.02.023.
23. A. Schmall, H. M. Al-tamari, S. Herold, M. Kampschulte, A. Weigert, A. Wietelmann, N. Vipotnik, F. Grimminger, W. Seeger, S. Savai Pullamsetti, and R. Savai. Macrophage and cancer cell cross-talk via ccr2 and cx3cr1 is a fundamental mechanism driving lung cancer. *American Journal of Respiratory and Critical Care Medicine*, 191:437–447, 12 2014. ISSN 1073-449X. doi: 10.1164/rccm.201406-1137OC.
24. D. Aldinucci, C.a Borghese, and N. Casagrande. The ccl5/ccr5 axis in cancer progression. *Cancers*, 12:1765, 7 2020. ISSN 2072-6694. doi: 10.3390/cancers12071765.
25. . Walens, A. V DiMarco, R. Lupo, B. R Kroger, J. S Damrauer, and J. V Alvarez. Ccl5 promotes breast cancer recurrence through macrophage recruitment in residual tumors. *eLife*, 8, 4 2019. ISSN 2050-084X. doi: 10.7554/eLife.43653.
26. S. Bai, Y. Wu, Y. Yan, H. Kang, J. Zhang, W. Ma, Y. Gao, B. Hui, R. Li, X. Zhang, and J. Ren. The effect of ccl5 on the immune cells infiltration and the prognosis of patients with kidney renal clear cell carcinoma. *International journal of medical sciences*, 17:2917–2925, 2020. ISSN 1449-1907. doi: 10.7150/ijms.51126.
27. E. S. Melese, E. Franks, R. A. Cederberg, B. T. Harbourne, R. Shi, B. J. Wadsworth, J. L. Collier, E. C. Halvorsen, F. Johnson, J. Luu, M. H. Oh, V. Lam, G. Krystal, S. B. Hoover, M. Raffeld, R. M. Simpson, A. M. Unni, W. L. Lam, S. Lam, N. Abraham, K. L. Bennewith, and W. W. Lockwood. Ccl5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development. *OncoImmunology*, 11, 12 2022. ISSN 2162-402X. doi: 10.1080/2162402X.2021.2010905.
28. L.-Y. Chang, Y.-C. Lin, J. Mahalingam, C.-T. Huang, T.-W. Chen, C.-W. Kang, H.-M. Peng, Y.-Y. Chu, J.-M. Chiang, A. Dutta, Y.-J. Day, T.-C. Chen, C.-T. Yeh, and C.-Y. Lin. Tumor-derived chemokine ccl5 enhances tgf-β–mediated killing of cd8+ t cells in colon cancer by t-regulatory cells. *Cancer Research*, 72:1092–1102, 3 2012. ISSN 0008-5472. doi: 10.1158/0008-5472.CAN-11-2493.
29. M. Gschwandtner, R. Derler, and K. S. Midwood. More than just attractive: How ccl2 influences myeloid cell behavior beyond chemotaxis. *Frontiers in Immunology*, 10, 12 2019. ISSN 1664-3224. doi: 10.3389/fimmu.2019.02759.
30. E. Sierra-Filardi, C. Nieto, Á. Domínguez-Soto, R. Barroso, P. Sanchez-Mateos, A. Puig-Kroger, M. Lopez-Bravo, J. Joven, C. Ardavin, J. L. Rodriguez-Fernandez, C. Sanchez-Torres, M. Mellado, and A. L. Corbi. Ccl2 shapes macrophage polarization by gm-csf and m-csf: Identification of ccl2/ccr2-dependent gene expression profile. *The Journal of Immunology*, 192:3858–3867, 4 2014. ISSN 0022-1767. doi: 10.4049/jimmunol.1302821.
31. A. C. Pirkey, W. Deng, D. Norman, A. Razazan, and D. J. Klinke. Head-to-Head Comparison of CCN4, DNMT3A, PTPN11, and SPARC as Suppressors of Anti-tumor Immunity. *Cell Mol Bioeng*, 16(5-6):431–442, Dec 2023.

Figure Legends

Figure 1 - B16F0 tumors have a faster intrinsic growth rate and are more immunogenic than YUMM1.7 tumors. Growth curves of B16F0 (A) and YUMM1.7 (B) tumors in immunocompetent C57BL/6 (black) and severely immunocompromised NSG (red) mice. Each curve corresponds to the tumor size in each mouse measured as a function of time. A mathematical model describing the growth kinetics (C) was regressed to the log-linear growth curves using a Markov Chain Monte Carlo approach. (D) The posterior distribution in the parameter corresponding to the proliferation rate (k_P) of YUMM1.7 (unshaded) and B16F0 (gray shaded) cell lines in NSG mice. (E) The posterior distribution in the log ratio of the proliferation rate in NSG mice (k_P) relative to the net proliferation rate ($k_P - k_D$) of the same cells in C57BL/6 mice. The posterior distribution for YUMM1.7 cells is shown as an unshaded curve and for B16F0 cells in shown as a shaded curve.

Figure 2 - Viability of B16F0 and YUMM1.7 cells in response to increasing concentrations of three small molecule drugs. Viability of YUMM1.7 (blue) and B16F0 (red) cells cultured *in vitro* with the indicated concentrations of PLX4720 (A), Mitoxantrone (B), and iCRT14 (C). Symbols represent results from four biological replicates at each concentration. The IC50s indicated were calculated by regressing dose-response curves ($100 \times (1 - x/(x + IC50))$, where x is the drug concentration), which are shown as curved lines, to data for each drug-cell combination.

Figure 3 - Primary PMEL1 CD8+ T cells lyse both B16F0 and YUMM1.7 cells. Pre-activated PMEL1 CD8+ T cells were co-cultured for 4 hours with target cells at the indicated effector to target ratios to assess cytotoxicity. Cytotoxicity was quantified using a CyQUANT LDH Cytotoxicity assay. Wild-type B16F0 and YUMM1.7 cell lines were used as targets after an overnight incubation with 250 U/mL of rmIFNγ. Mean +/- SD represent collective results from three biological replicates.

Figure 4 - IFN-gamma induces PD-L1 and MHC class I expression in both B16F0 and YUMM1.7 cells. Expression levels of PD-L1 (A, top row), H-2K^b (B, middle row), and H-2D^b (C, bottom row) in B16F0 (red) and YUMM1.7 (blue) were quantified by flow cytometry at baseline (left column) and after overnight incubation with 250 U/mL of IFNγ (middle column). Dot plots (right column) summarize differences in mean values of distributions among cell lines and conditions. Mean +/- SD represent collective results from three biological replicates. ANOVA with post-hoc Tukey tests were used to assess statistical significance, where (a, b, c, or d) denote statistically different groups.

Figure 5 - Tumors derived from YUMM1.7 cells have higher infiltration of lymphocytes compared to B16F0-derived tumors. (A) The percentage of live CD45+ cells isolated from tumors generated by inoculating s.c. with WT B16F0 (red) and YUMM1.7 (black) cells. CD45+ values were obtained from three different antibody panels that quantified T cells, B/NK cells, and myeloid cells in TIL isolates from each mouse (B16F0 n = 4; YUMM1.7 n = 3). p-values calculated using two-sided Student's t-test with equal variance. (B) A comparison of the ratio of NK cells (black), CD8+ T cells (red), CD4+ T cells (blue), and B cells (green) to live CD45+ TILs in tumors generated using WT B16F0 and YUMM1.7 cells (mean $\pm$ SD). (C) A comparison of the ratio of CD11c- (black) and CD11c+ (gray) macrophages, CD11c+ Mo-MDSCs (green), Mo-MDSCs (blue), and PMN-MDSCs (red) to live CD45+ TILs in tumors generated using WT B16F0 and YUMM1.7 cells (mean $\pm$ SD).

Figure 6 - The profile of cytokines, chemokines, and growth factors secreted into media conditioned by WT B16F0 and YUMM1.7 are different. Results from R&D Systems' Mouse XL Cytokine Array Kit of cytokine, chemokine, and growth factor expression by WT YUMM1.7 and B16F0 cells *in vitro*. Open circles represent results for specific cytokine probes while filled circles represent positive and negative controls. Dotted lines enclose a null distribution estimated from positive and negative controls. Particular secreted factors that are differentially expressed are annotated with their respective names.



Fig. 1. B16F0 tumors have a faster intrinsic growth rate and are more immunogenic than YUMM1.7 tumors.



Fig. 2. Viability of B16F0 and YUMM1.7 cells in response to increasing concentrations of three small molecule drugs.



Fig. 3. Primary PMEL1 CD8+ T cells lyse both B16F0 and YUMM1.7 cells.



Fig. 4. IFN-gamma induces PD-L1 and MHC class I expression in both B16F0 and YUMM1.7 cells.



Fig. 5. Tumors derived from YUMM1.7 cells have higher infiltration of lymphocytes compared to B16F0-derived tumors.



Fig. 6. The profile of cytokines, chemokines, and growth factor secreted into media conditioned by WT B16F0 and YUMM1.7 are different.


A
B16F0
10000
1000
100
10
Tumor Volume (mm3)
0
10
20
30
Time following injection (Days)
C57BL/6 (n=8)
NSG (n=5)


B
YUMM1.7
10000
1000
100
10
Tumor Volume (mm3)
10
20
30
40
Time following injection (Days)
C57BL/6 (n=5)
NSG (n=5)


C
Proliferation (kP)
Tumor
(CT)
Immune-mediated
Cell Death (kD)
$\frac{dC_T}{dt} = k_P \cdot C_T - k_D \cdot C_T$
$C_T(t = 0) = C_{T0}$


D
1
0
Density
YUMM1.7
B16F0
-1.0
-0.8
-0.6
-0.4
-0.2
$\ln\left[k_P\big|_{NSG}\right]$


E
1
0
Density
YUMM1.7
B16F0
-0.4
-0.2
0.0
0.2
0.4
$\ln\left[\frac{k_P|_{NSG}}{(k_P - k_D)|_{C57BL/6}}\right]$


A
B16F0 IC50 = 138.6 µM
YUMM1.7
IC50 = 1.738 µM
Viability (% of control)
PLX4720 conc (µM)
0
20
40
60
80
100
120
140
0
0.1
1
10
100


B
B16F0
IC50 = 68.07 nM
YUMM1.7
IC50 = 9.528 nM
Viability (% of control)
Mitoxantrone conc (nM)
0
20
40
60
80
100
120
0
1
10
100
1000


C
B16F0
IC50 = 3.429 µM
YUMM1.7
IC50 = 3.372 µM
Viability (% of control)
iCRT14 conc (µM)
0
20
40
60
80
100
120
0
0.1
1
10
100


B16F0
YUMM1.7
% Specific Cytotoxicity
120
100
80
60
40
20
0
2:1
10:1
50:1
Effector:Target Ratio


No IFNγ
+ IFNγ
A
B
C
Count
PD-L1
H2Kb
H2Db
MFI (PD-L1)
MFI (H-2K^b)
MFI (H-2D^b)
a
b
c
d
B16F0
B16F0 + IFNγ
Ym1.7
Ym1.7 + IFNγ


A
Live CD45+ cells
(% of Total Live cells)
40
30
20
10
0
YUMM1.7
B16F0
P-value
0.0084
10^2
10^3
10^4
Tumor size (mm³)


B
Ratio to Live CD45⁺ cells
1
0.1
10^{-2}
B16F0
YUMM1.7
NK cells
(Live CD45+ CD3e- NK1.1+ B220-)
CD8+ T cells
(Live CD45+ CD3e+ CD4- CD8a+)
CD4+ T cells
(Live CD45+ CD3e+ CD4+ CD8a-)
B cells
(Live CD45+ CD3e- NK1.1- B220+)


C
Ratio to Live CD45⁺ cells
1
0.1
10^{-2}
10^{-3}
B16F0
YUMM1.7
CD11c- Macrophages
(Live CD45+ CD11b+ CD11c- GR1- F4/80+ MHCII-)
CD11c+ Macrophages
(Live CD45+ CD11b+ CD11c+ GR1- F4/80+ MHCII+)
CD11c+ Mo-MDSC
(Live CD45+ CD11b+ CD11cint GR1+ F4/80+ MHCII-:)
Mo-MDSC
(Live CD45+ CD11b+ CD11c- GR1+ F4/80+ MHCII+)
PMN-MDSC
(Live CD45+ CD11b+ CD11c- GR1+ F4/80- MHCII+)


YUMM1.7 vs B16F0
B16F0 WT / YUMM1.7 WT Expression
Average Expression
1000
100
10
1
0.1
0.01
0.001
10
100
1000
10000
Angiopoietin-2
VEGF
CCN4
Endoglin
CCL5
Coagulation Factor III
M-CSF
OPN
PCSK9
IL28A/B
MMP2
IGFBP-5
Serpin F1
CCL2
IGFBP-6
CD62P
Amphiregulin
CX3CL1
CXCL1
MMP3
Endostatin